Quotient Limited Quick Ratio (QTNT) starting from the third quarter 2022 to third quarter 2021, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Quotient Limited  (NASDAQ: QTNT)

Quotient Limited's Quick Ratio

QTNT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2022, Quick Ratio fell to 0.4 below Quotient Limited average.

Within In Vitro & In Vivo Diagnostic Substances industry 22 other companies have achieved higher Quick Ratio than Quotient Limited in third quarter 2022. While Quick Ratio total ranking in the third quarter 2022 has deteriorated compared to the prior quarter from 1485 to 3840.

Explain Quick Ratio?
How much Cash & cash equivalents QTNT´s has?
What are QTNT´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

QTNT Quick Ratio (Dec 31 2022)
Q3		 (Sep 30 2022)
Q2		 (Jun 30 2022)
Q1		 (Mar 31 2022)
Q4		 (Dec 31 2021)
Q3
Y / Y Current Liabilities Change -88.02 % -3.77 % -50.18 % 355.35 % 390.85 %
Y / Y Cash & cash equivalent Change -88.5 % -80.95 % -70.82 % -39.39 % -22.82 %
Quick Ratio MRQ 0.4 0.92 1.68 0.25 0.42
QTNT's Total Ranking # 3840 # 1485 # 1582 # 1470 #
Seq. Current Liabilities Change 0.45 % 2 % -89.32 % 9.42 % 707.18 %
Seq. Cash & cash equivalent Change -55.81 % -44.46 % -28.15 % -34.78 % -26.8 %



Quick Ratio third quarter 2022 Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 23
Healthcare Sector # 1080
Overall Market # 3840


Quick Ratio Statistics
High Average Low
13.06 2.45 0.39
(Dec 31 2018)   (Jun 30 2015)




Financial Statements
Quotient Limited's Current Liabilities $ 30 Millions Visit QTNT's Balance sheet
Quotient Limited's Cash & cash equivalent $ 12 Millions Visit QTNT's Balance sheet
Source of QTNT's Sales Visit QTNT's Sales by Geography


Cumulative Quotient Limited's Quick Ratio

QTNT's Quick Ratio for the trailling 12 Months

QTNT Quick Ratio

 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months		 (Dec 31 2021)
12 Months
Y / Y Current Liabilities TTM Growth -9.3 % 190.37 % 173.23 % 235.01 % 156.77 %
Y / Y Cash & cash equivalent TTM Growth -70.36 % -55.44 % -37.13 % -4.66 % 2.23 %
Quick Ratio TTM 0.43 0.43 0.63 0.79 1.32
Total Ranking TTM # 5897 # 2694 # 5676 # 1306 #
Seq. Current Liabilities TTM Growth -37.77 % -0.2 % -4.8 % 53.41 % 99.22 %
Seq. Cash & cash equivalent TTM Growth -37.17 % -31.71 % -24.59 % -8.4 % -5.53 %

Quick ratio ranking by company, industry and sector >> Back to QTNT Financial Strength Comparisons >> Go to Compare QTNT Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in QTNT's Current Liabilities to $29.63 millions, cumulative Quick Ratio to 0.43 below the QTNT average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 22 other companies have achieved higher Quick Ratio than Quotient Limited. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2022 from 2694 to 5897.

Explain Quick Ratio?
How much Cash & cash equivalents QTNT´s has?
What are QTNT´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the In Vitro & In Vivo Diagnostic Substances Industry # 23
Healthcare Sector # 1229
Within the Market # 5897


trailing twelve months Quick Ratio Statistics
High Average Low
4.05 2.32 0.95
(Mar 31 2020)   (Mar 31 2016)




Companies with similar Quick Ratio in the quarter ending Dec 31 2022, within In Vitro & In Vivo Diagnostic Substances Industry Quick RatioDec 31 2022 MRQ Cash & cash equivalentDec 31 2022 MRQ Current Liabilities
Meridian Bioscience Inc   0.94 $ 74.098  Millions$ 78.577  Millions
Aspira Women s Health inc   0.82 $ 13.306  Millions$ 16.174  Millions
Myriad Genetics Inc   0.63 $ 114.900  Millions$ 181.100  Millions
Volitionrx Limited  0.63 $ 10.867  Millions$ 17.386  Millions
Immucell Corporation  0.53 $ 5.792  Millions$ 10.930  Millions
Quotient Limited  0.40 $ 11.934  Millions$ 29.631  Millions
Trinity Biotech Plc  0.35 $ 8.412  Millions$ 23.754  Millions
Nymox Pharmaceutical Corporation  0.35 $ 1.431  Millions$ 4.041  Millions
Quidelortho Corp  0.35 $ 345.000  Millions$ 995.400  Millions
Navidea Biopharmaceuticals Inc   0.20 $ 1.996  Millions$ 9.923  Millions
Idexx Laboratories Inc  0.08 $ 112.546  Millions$ 1,382.547  Millions

Date modified: 2026-09-08T15:22:10+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.